Strongbridge Biopharma Reports Positive Results in Phase 3 SONICS Study of RECORLEV

published 9:45 pm ET August 8th, 2018

On August 8, Strongbridge Biopharma plc (SBBP) announced top-line results from its Phase 3 SONICS study evaluating RECORLEVTM(levoketoconazole) for the treatment of endogenous Cushing’s syndrome. The open-label, single-arm SONICS study produced statistically significant results of its pre-specified primary endpoint. At six months, 30% of patients demonstrated a normalization rate of Urinary Free Cortisol. Rocket Tickers […]

August 8th, 2018 By Kim Newsletter 0 comments

Read More

0Comments

Reata Pharmaceuticals Reports Positive Phase 2 Results From Two Clinical Trials

published 9:24 pm ET July 23rd, 2018

On July 23, Reata Pharmaceuticals, Inc. (RETA) announced results from two Phase 2 clinical trials of bardoxolone in patients with chronic kidney disease. The one-year results for the Phase 2 portion of CARDINAL, a study of bardoxolone in patients with chronic kidney disease due to Alport syndrome, found that patients had no drug-related negative side […]

July 23rd, 2018 By Kim Newsletter 0 comments

Read More

0Comments

Aclaris Therapeautics Reports Positive Phase 2 Clinical Trial Results

published 10:36 pm ET July 9th, 2018

On June 28, Aclaris Therapeutics (ACRS) reported positive interim results from its Phase 2 clinical trial of AA-202 Topical. The drug is an investigational topical to treat two of the more severe variants of Alopecia Areata. Patients did not experience any treatment-related serious adverse events, and results for the full patient sample will be reported […]

July 9th, 2018 By Kim Newsletter 0 comments

Read More

0Comments

IsoRay Receives FDA 510(k) Clearance for GammaTileTM Therapy

published 9:24 pm ET July 9th, 2018

On July 9, IsoRay, Inc. (ISR) and GT Medical Technologies, Inc. announced they received FDA 510(k) regulatory clearance for their brachytherapy technology, known as GammaTileTMTherapy. The therapy incorporates proprietary Cesium-131 seeds within customizable collagen-based carriers to treat recurrent brain tumors. The two companies previously executed a ten-year collaborative development agreement.   Rocket Tickers detected the […]

July 9th, 2018 By Kim Newsletter 0 comments

Read More

0Comments

June 2018 Scorecard

published 12:38 pm ET July 9th, 2018

The June 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar

July 9th, 2018 By Signal Newsletter 0 comments

Read More

0Comments

Zafgen Reports Positive Phase 2 Clinical Trial Results for ZGN-1061

published 11:33 pm ET July 2nd, 2018

On June 23, Zafgen, Inc. (ZFGN) reported positive results from the company’s Phase 2 clinical trial of ZGN-1061. The trial is designed to prove the drug’s efficacy and safety in patients with type 2 diabetes and to establish a minimally effective dose. Zafgen reported that the patients had no treatment-related serious adverse events.   Rocket Tickers […]

July 2nd, 2018 By Kim Newsletter 0 comments

Read More

0Comments

Global Blood Therapeutics Reports Positive Phase 3 HOPE Study Results

published 10:38 pm ET June 27th, 2018

Global Blood Therapeutics, Inc. (GBT) announced its positive top-line Phase 3 clinical trial data on June 27. The results are from Part A of the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymEmerization) Study to evaluate the use of voxelotor as a treatment for sickle cell disease. On the primary endpoint, patients […]

June 27th, 2018 By Kim Newsletter 0 comments

Read More

0Comments

Ironwood Pharmaceuticals Receives FDA Orphan Drug Designation for Olinciguat

published 10:41 pm ET June 15th, 2018

Ironwood Pharmaceuticals Inc. (IRWD) announced on June 7 that the FDA granted Orphan Drug Designation to Olinciguat (IW-1701) for patients with sickle cell disease. The FDA grants orphan status to drugs that are intended to treat rare disorders that affect fewer than 200,000 patients in the United States. The designation gives the developer fee waivers and […]

June 15th, 2018 By Kim Newsletter 0 comments

Read More

0Comments

May 2018 Scorecard

published 12:36 pm ET June 9th, 2018

The May 2018 scorecard for the signals generated from Rocket Tickers can be downloaded here. For more information regarding how you can trade these signals, see the article Trading Clinical Trials Try Rocket Tickers 30 days for free and cancel anytime! Subscribe here and check out the Training Webinar

June 9th, 2018 By Signal Newsletter 0 comments

Read More

0Comments

Published Study Supports Global Medical’s Expandable Lateral Technology

published 10:52 pm ET May 23rd, 2018

On May 15, Global Medical, Inc. (GMED) reported the results of a medical study that supported the benefits of the company’s Globus expandable lateral spacers. The study “Clinical and radiographic analysis of expandable versus static lateral lumbar interbody fusion devices with two-year follow-up” was published in the Journal of Spine Surgery. Dr. Joseph O’Brien, MD, […]

May 23rd, 2018 By Kim Newsletter 0 comments

Read More

0Comments